New cancer drug enters human testing for Tough-to-Treat cancers
NCT ID NCT03900442
Summary
This early-stage study tested a new drug called PTX-100 in 25 patients with advanced cancers that had stopped responding to standard treatments. The main goals were to check the drug's safety, how the body processes it, and its initial effects on cancer-related proteins. Patients received the drug through an IV for five days every two weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epworth Healthcare
Melbourne, Victoria, 3002, Australia
Conditions
Explore the condition pages connected to this study.